{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:58:11Z","timestamp":1792425491341,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has previously demonstrated its efficacy and safety in chronic kidney disease (CKD) associated with diabetes mellitus. Given its therapeutic potential, finerenone has been preliminarily explored in clinical practice for non-diabetic CKD patients. The effectiveness and safety in this population require further investigation in a real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, real-world analysis included non-diabetic CKD patients receiving finerenone. The main clinical outcomes assessed were changes in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Serum potassium (sK<jats:sup>+<\/jats:sup>) levels were also monitored. Data were collected at baseline, and then at 1\u00a0month and 3\u00a0months following treatment initiation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Totally, 16 patients were included. There was a notable decrease in UACR from 1-month post-treatment, with a further reduction at 3\u00a0months, resulting in a median reduction of 200.41\u00a0mg\/g (IQR, 84.04\u20131057.10\u00a0mg\/g; <jats:italic>P<\/jats:italic>\u2009=\u20090.028; percent change, 44.52% [IQR, 31.79\u201365.42%]). The average eGFR at baseline was 80.16\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>, with no significant change after 1\u00a0month (80.72\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>, <jats:italic>P<\/jats:italic>\u2009=\u20090.594) and a slight numerical increase to 83.45\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2009=\u20090.484) after 3\u00a0months. During the 3-month follow-up, sK<jats:sup>+<\/jats:sup> levels showed only minor fluctuations, with no significant differences compared to baseline, and remained within the normal range throughout the treatment period. No treatment discontinuation or hospitalization due to hyperkalemia was observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In non-diabetic CKD patients, finerenone showed good effectiveness and safety within a 3-month follow-up period. This study provides valuable real-world evidence supporting the use of finerenone in non-diabetic CKD and highlights the need for future large-scale prospective research to further validate its efficacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-024-04142-1","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:02:01Z","timestamp":1720616521000},"page":"3877-3885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study"],"prefix":"10.1007","volume":"56","author":[{"given":"Li","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"4142_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.88","volume":"3","author":"P Romagnani","year":"2017","unstructured":"Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M et al (2017) Chronic kidney disease. Nat Rev Dis Primers 3:1\u201324. https:\/\/doi.org\/10.1038\/nrdp.2017.88","journal-title":"Nat Rev Dis Primers"},{"key":"4142_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Supp 12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Supp"},{"key":"4142_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrneph.2016.163","volume":"13","author":"RJ Glassock","year":"2017","unstructured":"Glassock RJ, Warnock DG, Delanaye P (2017) The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol 13:104\u2013114. https:\/\/doi.org\/10.1038\/nrneph.2016.163","journal-title":"Nat Rev Nephrol"},{"key":"4142_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F (2022) Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014Mechanistic and therapeutic effects. Nat Rev Nephrol 18:56\u201370. https:\/\/doi.org\/10.1038\/s41581-021-00490-8","journal-title":"Nat Rev Nephrol"},{"key":"4142_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","volume":"12","author":"T Nakamura","year":"2022","unstructured":"Nakamura T, Girerd S, Jaisser F, Barrera-Chimal J (2022) Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl 12:12\u201318. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.004","journal-title":"Kidney Int Suppl"},{"key":"4142_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754239","volume":"12","author":"D Kawanami","year":"2021","unstructured":"Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H et al (2021) Mineralocorticoid receptor antagonists in diabetic kidney disease. Front Pharmacol 12:754239. https:\/\/doi.org\/10.3389\/fphar.2021.754239","journal-title":"Front Pharmacol"},{"key":"4142_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F (2022) Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol 18:56\u201370. https:\/\/doi.org\/10.1038\/s41581-021-00490-8","journal-title":"Nat Rev Nephrol"},{"key":"4142_CR8","doi-asserted-by":"publisher","first-page":"F723","DOI":"10.1152\/ajprenal.00480.2006","volume":"293","author":"A Zhang","year":"2007","unstructured":"Zhang A, Jia Z, Guo X, Yang T (2007) Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 293:F723\u2013F731. https:\/\/doi.org\/10.1152\/ajprenal.00480.2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"4142_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42:152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"4142_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/ndt\/gfac284","volume":"38","author":"LP Gregg","year":"2023","unstructured":"Gregg LP, Navaneethan SD (2023) Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant 38:1355\u20131365. https:\/\/doi.org\/10.1093\/ndt\/gfac284","journal-title":"Nephrol Dial Transplant"},{"key":"4142_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/dom.13983","volume":"22","author":"O Al Dhaybi","year":"2020","unstructured":"Al Dhaybi O, Bakris GL (2020) Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab 22:69\u201376. https:\/\/doi.org\/10.1111\/dom.13983","journal-title":"Diabetes Obes Metab"},{"key":"4142_CR12","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman SC, Bakris GL (2023) Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care 46:1574\u20131586. https:\/\/doi.org\/10.2337\/dci23-0030","journal-title":"Diabetes Care"},{"key":"4142_CR13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","volume":"81","author":"JE Frampton","year":"2021","unstructured":"Frampton JE (2021) Finerenone: First Approval. Drugs 81:1787\u20131794. https:\/\/doi.org\/10.1007\/s40265-021-01599-7","journal-title":"Drugs"},{"key":"4142_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102638","volume":"16","author":"AK Singh","year":"2022","unstructured":"Singh AK, Singh A, Singh R, Misra A (2022) Finerenone in diabetic kidney disease: a systematic review and critical appraisal. Diabetes Metab Syndr 16:102638. https:\/\/doi.org\/10.1016\/j.dsx.2022.102638","journal-title":"Diabetes Metab Syndr"},{"key":"4142_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314:884\u2013894. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"key":"4142_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"4142_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000531997","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xie J, Hao C, Li X, Zhu D, Zheng H et al (2023) Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China. Kidney dis (Basel, Switzerland) 9:498\u2013506. https:\/\/doi.org\/10.1159\/000531997","journal-title":"Kidney dis (Basel, Switzerland)"},{"key":"4142_CR18","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"4142_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"4142_CR20","doi-asserted-by":"publisher","first-page":"1114894","DOI":"10.3389\/fendo.2023.1114894","volume":"14","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Sinha B (2023) Finerenone in type 2 diabetes and renal outcomes: a random-effects model meta-analysis. Front Endocrinol (Lausanne) 14:1114894. https:\/\/doi.org\/10.3389\/fendo.2023.1114894","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4142_CR21","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1111\/ajt.13917","volume":"16","author":"S Anjum","year":"2016","unstructured":"Anjum S, Muzaale AD, Massie AB, Bae S, Luo X, Grams ME et al (2016) Patterns of end-stage renal disease caused by diabetes, hypertension, and glomerulonephritis in live kidney donors. Am J Transplant 16:3540\u20133547. https:\/\/doi.org\/10.1111\/ajt.13917","journal-title":"Am J Transplant"},{"key":"4142_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1470320311412811","volume":"13","author":"N Tsuboi","year":"2012","unstructured":"Tsuboi N, Kawamura T, Okonogi H, Ishii T, Hosoya T (2012) The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 13:113\u2013117. https:\/\/doi.org\/10.1177\/1470320311412811","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"4142_CR23","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453\u20132463. https:\/\/doi.org\/10.1093\/eurheartj\/eht187","journal-title":"Eur Heart J"},{"key":"4142_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"A Levin","year":"2013","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE et al (2013) Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements 3:1\u2013150","journal-title":"Kidney international supplements"},{"key":"4142_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"issue":"350\u201360","key":"4142_CR26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.02.335","volume":"78","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Weldegiorgis M, Herrington WG, Ohkuma T, Smith M, Woodward M (2021) Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression. Am J Kidney Dis 78(350\u201360):e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.02.335","journal-title":"Am J Kidney Dis"},{"key":"4142_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","volume":"53","author":"K Luettges","year":"2022","unstructured":"Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R et al (2022) Finerenone reduces renal RORgammat gammadelta T cells and protects against cardiorenal damage. Am J Nephrol 53:552\u2013564. https:\/\/doi.org\/10.1159\/000524940","journal-title":"Am J Nephrol"},{"key":"4142_CR28","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Rosenkranz KAT, Kusunoki Y, Li C, Klaus M, Gross O et al (2023) Finerenone Added to RAS\/SGLT2 Blockade for CKD in alport syndrome. results of a randomized controlled trial with Col4a3-\/- mice. J Am Soc Nephrol 34:1513\u20131520. https:\/\/doi.org\/10.1681\/ASN.0000000000000186","journal-title":"J Am Soc Nephrol"},{"key":"4142_CR29","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S et al (2023) Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes\u202f: A mediation Analysis. Ann Intern Med 176:1606\u20131616. https:\/\/doi.org\/10.7326\/M23-1023","journal-title":"Ann Intern Med"},{"key":"4142_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.mcna.2023.03.001","volume":"107","author":"AM Aklilu","year":"2023","unstructured":"Aklilu AM (2023) Diagnosis of chronic kidney disease and assessing glomerular filtration rate. Med Clin North Am 107:641\u2013658. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.001","journal-title":"Med Clin North Am"},{"key":"4142_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jfma.2020.07.022","volume":"120","author":"YT Chen","year":"2021","unstructured":"Chen YT, Chan CK, Li WY, Huang TM, Lai TS, Wu VC et al (2021) Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients. J Formos Med Assoc 120:641\u2013650. https:\/\/doi.org\/10.1016\/j.jfma.2020.07.022","journal-title":"J Formos Med Assoc"},{"key":"4142_CR32","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","volume":"14","author":"ZC Dai","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW (2023) Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol 14:1213473. https:\/\/doi.org\/10.3389\/fimmu.2023.1213473","journal-title":"Front Immunol"},{"key":"4142_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110210","volume":"195","author":"Q Chen","year":"2023","unstructured":"Chen Q, Liang Y, Yan J, Du Y, Li M, Chen Z et al (2023) Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis. Diabetes Res Clin Pract 195:110210. https:\/\/doi.org\/10.1016\/j.diabres.2022.110210","journal-title":"Diabetes Res Clin Pract"},{"key":"4142_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T et al (2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2:944\u2013953. https:\/\/doi.org\/10.1016\/S2213-8587(14)70194-9","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04142-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:07:11Z","timestamp":1730732831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04142-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04142-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}